Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

An observational study to assess persistence, adherence, quality of life, and treatment satisfaction in patients beginning therapy with the Avonex® PEN™ (PERSIST)
Bullous pemphigoid in a patient with multiple sclerosis being treated with human immunoglobulin.
The little compound that could: how phenytoin changed drug discovery and development.
Recombinant T Cell Receptor Ligands Improve Outcome After Experimental Cerebral Ischemia.
Demyelination: the role of reactive oxygen and nitrogen species.
Santhera enters agreement with Columbia University to investigate additional potential of Catena® in MELAS
Secret talk between adipose tissue and central nervous system via secreted factors-an emerging frontier in the neurodegenerative research.
Brain gadolinium enhancement along the ventricular and leptomeningeal regions in patients with aquaporin-4 antibodies in cerebral spinal fluid.
Vitamin D and multiple sclerosis: a critical review and recommendations on treatment.
Visual Functional and Histopathological Correlation in Experimental Autoimmune Optic Neuritis.
Progressive Multifocal Leukoencephalopathy
The effects of massage therapy on multiple sclerosis patients' quality of life and leg function.
Apitope Announces Completion of Enrolment in Phase IIA Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis
Effects of natalizumab treatment on the CSF proteome of multiple sclerosis patients.
Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects with Multiple Sclerosis
Genzyme’s Lemtrada™ approved in Canada for treatment of multiple sclerosis
Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
High dose thiamine improves fatigue in multiple sclerosis.
Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.
Exogenous schwann cells migrate, remyelinate and promote clinical recovery in experimental auto-immune encephalomyelitis.
Phase IV Study Reports Multiple Sclerosis Success with Teriflunomide
Early Growth Response Gene-2 Controls IL-17 Expression and Th17 Differentiation by Negatively Regulating Batf.
Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.
Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta.
Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis.

Pages